Rep. Barton cancels FDA advertising hearing.
This article was originally published in The Gray Sheet
Executive SummaryFDA INFORMATION DISSEMINATION OVERSIGHT HEARING CANCELED by House Commerce/Oversight Subcommittee Chairman Joe Barton (R-Tex.). The session on FDA advertising "censorship," which had been scheduled for Nov. 29, has not been rescheduled, according to the subcommittee.
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.